What question did this study set out to answer?

To evaluate the efficacy and safety of early administration of sotrovimab, a pan-sarbecovirus monoclonal antibody, in preventing disease progression among nonhospitalized patients with symptomatic Covid-19 at high risk for severe illness.

October 27, 2021New England Journal of Medicine

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates reduced hospitalization and death with sotrovimab in high-risk Covid-19 patients, indicating effective early monoclonal antibody therapy.

Key Points

To evaluate the efficacy and safety of early administration of sotrovimab, a pan-sarbecovirus monoclonal antibody, in preventing disease progression among nonhospitalized patients with symptomatic Covid-19 at high risk for severe illness.
In an ongoing, multicenter, double-blind, phase 3 trial (COMET-ICE; NCT04545060), nonhospitalized patients with symptomatic Covid-19 (≤5 days after symptom onset) and at least one risk factor for progression were randomly assigned 1:1 to receive a single 500-mg infusion of sotrovimab or placebo.
The primary efficacy endpoint was hospitalization for >24 hours for any cause or death within 29 days after randomization, evaluated in an intention-to-treat population of 583 patients (291 sotrovimab, 292 placebo).
Disease progression leading to hospitalization or death occurred in 3 of 291 patients (1%) in the sotrovimab group compared to 21 of 292 patients (7%) in the placebo group, representing an 85% relative risk reduction (97.24% CI, 44 to 96; P = 0.002).
Five patients in the placebo group required intensive care admission, including 1 death by day 29, whereas no such events occurred in the sotrovimab group.
In the safety population of 868 patients, adverse events occurred in 17% of sotrovimab recipients and 19% of placebo recipients, with serious adverse events reported in 2% and 6%, respectively.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6a8074882ea91e47663d5a10 https://doi.org/10.1056/nejmoa2107934

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates reduced hospitalization and death with sotrovimab in high-risk Covid-19 patients, indicating effective early monoclonal antibody therapy.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Discussion

Member takes

Implication

Key Points

Cite This Study

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider